The EMA has launched a pilot program allowing companies to submit data generated by new approach methodologies (NAMs) for consideration outside the context of a formal marketing application. The initiative is aimed at testing whether NAM evidence can support regulatory evaluation and potentially accelerate the shift away from certain preclinical animal studies. For sponsors and CMC/TOX teams, the pilot signals that NAM-generated data may be more usable earlier in development, if companies can package it to match regulators’ evaluation needs. The program’s structure also suggests a pathway for aligning future safety evidence requirements with modern mechanistic and in vitro/in silico tools—without waiting for full standalone regulatory frameworks.